NYSE: MANEVeradermics Inc Stock
$93.87+2.00 (+2.18%)
Updated Jun 18, 2026
MANE Price
$93.87
Fair Value Price
N/A
Market Cap
$3.92B
52 Week Low
$32.00
52 Week High
$117.71
P/E
N/A
P/B
10.04x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
N/A
Beta
1
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MANE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MANE
Ranked#173 of 465
Ranked#173 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important MANE news, forecast changes, insider trades & much more!
MANE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MANE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MANE is poor value based on its book value relative to its share price (10.04x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
MANE's short-term assets ($397.07M) exceed its short-term liabilities ($6.72M)
Short-term Liabilities Financials
MANE's short-term assets ($397.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more MANE due diligence checks available for Premium users.
Valuation
MANE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.04x
Industry
4.95x
MANE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MANE's financial health
Profit margin
Revenue
$0.0
Net Income
-$30.0M
Profit Margin
0%
Assets to liabilities
Assets
$397.4M
Liabilities
$6.7M
Debt to equity
0.02
MANE's short-term assets ($397.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MANE's short-term assets ($397.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MANE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.2M
Investing
-$101.3M
Financing
$269.1M
MANE vs Biotech Stocks
Veradermics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.